Erratum: A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells

Detalles Bibliográficos
Autores principales: Cheadle, E J, Lipowska-Bhalla, G, Dovedi, S J, Fagnano, E, Klein, C, Honeychurch, J, Illidge, T M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Erratum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7609297/
https://www.ncbi.nlm.nih.gov/pubmed/28751765
http://dx.doi.org/10.1038/leu.2017.218
_version_ 1783605001693691904
author Cheadle, E J
Lipowska-Bhalla, G
Dovedi, S J
Fagnano, E
Klein, C
Honeychurch, J
Illidge, T M
author_facet Cheadle, E J
Lipowska-Bhalla, G
Dovedi, S J
Fagnano, E
Klein, C
Honeychurch, J
Illidge, T M
author_sort Cheadle, E J
collection PubMed
description
format Online
Article
Text
id pubmed-7609297
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-76092972020-11-05 Erratum: A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells Cheadle, E J Lipowska-Bhalla, G Dovedi, S J Fagnano, E Klein, C Honeychurch, J Illidge, T M Leukemia Erratum Nature Publishing Group UK 2017-07-28 2017 /pmc/articles/PMC7609297/ /pubmed/28751765 http://dx.doi.org/10.1038/leu.2017.218 Text en © Macmillan Publishers Limited, part of Springer Nature. 2017 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Erratum
Cheadle, E J
Lipowska-Bhalla, G
Dovedi, S J
Fagnano, E
Klein, C
Honeychurch, J
Illidge, T M
Erratum: A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells
title Erratum: A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells
title_full Erratum: A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells
title_fullStr Erratum: A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells
title_full_unstemmed Erratum: A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells
title_short Erratum: A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells
title_sort erratum: a tlr7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via nk cells and cd4 t cells
topic Erratum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7609297/
https://www.ncbi.nlm.nih.gov/pubmed/28751765
http://dx.doi.org/10.1038/leu.2017.218
work_keys_str_mv AT cheadleej erratumatlr7agonistenhancestheantitumorefficacyofobinutuzumabinmurinelymphomamodelsviankcellsandcd4tcells
AT lipowskabhallag erratumatlr7agonistenhancestheantitumorefficacyofobinutuzumabinmurinelymphomamodelsviankcellsandcd4tcells
AT dovedisj erratumatlr7agonistenhancestheantitumorefficacyofobinutuzumabinmurinelymphomamodelsviankcellsandcd4tcells
AT fagnanoe erratumatlr7agonistenhancestheantitumorefficacyofobinutuzumabinmurinelymphomamodelsviankcellsandcd4tcells
AT kleinc erratumatlr7agonistenhancestheantitumorefficacyofobinutuzumabinmurinelymphomamodelsviankcellsandcd4tcells
AT honeychurchj erratumatlr7agonistenhancestheantitumorefficacyofobinutuzumabinmurinelymphomamodelsviankcellsandcd4tcells
AT illidgetm erratumatlr7agonistenhancestheantitumorefficacyofobinutuzumabinmurinelymphomamodelsviankcellsandcd4tcells

Ejemplares similares